Evaluation of generation 2 and 3 poly(propylenimine) dendrimers for the potential cellular delivery of antisense oligonucleotides targeting the epidermal growth factor receptor

被引:71
|
作者
Hollins, AJ
Benboubetra, M
Omidi, Y
Zinselmeyer, BH
Schatzlein, AG
Uchegbu, IF
Akhtar, S [1 ]
机构
[1] Univ Wales Coll Cardiff, Welsh Sch Pharm, Ctr Genome Based Therapeut, Cardiff CF10 3XF, S Glam, Wales
[2] Univ Setif, Fac Sci, Lab Appl Biochem, Setif 19000, Algeria
[3] Tabriz Univ Med Sci, Dept Pharmaceut, Tabriz 5166 15731, Iran
[4] Univ Strathclyde, Dept Pharmaceut Sci, Glasgow G4 0NR, Lanark, Scotland
[5] Univ Glasgow, Dept Med Oncol, Canc Res Campaign, Glasgow G61 1BD, Lanark, Scotland
关键词
A431; cells; antisense oligodeoxynucleotide; epidermal growth factor receptor; gene delivery; poly(propylenimine) dendrimer;
D O I
10.1023/B:PHAM.0000019300.04836.51
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. To evaluate low generation, G2 and G3, poly(propylenimine) dendrimers for the potential cellular delivery of antisense oligonucleotides (ODNs) targeting the epidermal growth factor receptor (EGFR) in A431 epidermoid carcinoma cells. Methods. Cell cytotoxicity of the dendrimers was evaluated using trypan blue exclusion assays. Cellular uptake studies of fluorescently labeled ODNs were performed using fluorescence-activated cell sorting analysis. Intracellular fate of dendrimer-delivered ODNs was assessed in both fixed and live cells using fluorescent microscopy. Antisense ODN activity was assessed in terms of cancer cell growth, inhibition of target EGFR protein, and reduction in mRNA levels. Results. G2 dendrimer (DAB-8) was less toxic than G3 (DAB-16) dendrimer in A431 cells, with IC50 of >175 and approximate to30 mug/ml, respectively. Uptake of fluorescently labeled ODN: dendrimer complexes was increased by up to 100-fold compared to a marker of fluid-phase endocytosis and up to 9-fold over free ODN at the optimal dendrimer: ODN (w/w) ratio of 5:1. Uptake of dendrimer: ODN complexes was significantly reduced at 4degreesC (p < 0.05). Live cell fluorescent microscopy resulted in an intracellular distribution of dendrimer: ODN complexes that was suggestive of endocytic uptake; in contrast, cell fixation resulted in an artefactual nuclear localization. Treatment of A431 cells with anti-EGFR antisense ODN: dendrimer complexes inhibited cell growth, protein, and mRNA expression to levels comparable to Oligofectamine-mediated delivery. Conclusions. G2 and G3 poly(propylenimine) dendrimers markedly improved the delivery and activity of ODNs and thus may represent general reagents for the delivery of ODNs to cells in culture.
引用
下载
收藏
页码:458 / 466
页数:9
相关论文
共 50 条
  • [31] Human Epidermal Growth Factor Receptor 2/Human Epidermal Growth Factor Receptor 3 PET Imaging Challenges and Opportunities
    Ducharme, Maxwell
    Mansur, Ameer
    Sligh, Luke
    Ulaner, Gary A.
    Lapi, Suzanne E.
    Sorace, Anna G.
    PET CLINICS, 2023, 18 (04) : 543 - 555
  • [32] TARGETING EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) AND HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 EXPRESSING BLADDER CANCER USING COMBINATION PHOTOIMMUNOTHERAPY (PIT)
    Siddiqui, Mohammad
    Railkar, Reema
    Sanford, Thomas
    Choyke, Peter
    Kobayashi, Hisataka
    Agarwal, Piyush
    JOURNAL OF UROLOGY, 2017, 197 (04): : E915 - E915
  • [33] Targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 expressing bladder cancer using combination photoimmunotherapy (PIT).
    Siddiqui, Mohammad Rashid
    Railkar, Reema S.
    Sanford, Thomas
    Choyke, Peter L.
    Kobayashi, Hisataka
    Agarwal, Piyush K.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [34] Efficient Epidermal Growth Factor Receptor Targeting Oligonucleotide as a Potential Molecule for Targeted Cancer Therapy
    Wang, Tao
    Philippovich, Svetlana
    Mao, Jun
    Veedu, Rakesh N.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (19)
  • [35] Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck
    Thomas, Sufi Mary
    Ogagan, Michelene Jeter
    Freilino, Maria L.
    Strychor, Sandy
    Walsh, Dustin R.
    Gooding, William E.
    Grandis, Jennifer Rubin
    Zamboni, William C.
    MOLECULAR PHARMACOLOGY, 2008, 73 (03) : 627 - 638
  • [36] The epidermal growth factor receptor and human topoisomerases represent potential cellular targets of oligomeric procyanidins
    Fridrich, Diana
    Kern, Melanie
    Fritz, Jessica
    Pahlke, Gudrun
    Koehler, Nils
    Winterhalter, Peter
    Marko, Doris
    MOLECULAR NUTRITION & FOOD RESEARCH, 2007, 51 (02) : 192 - 200
  • [37] Preclinical evaluation of radiolabelled nimotuzumab, a promising monoclonal antibody targeting the epidermal growth factor receptor
    Barta, Pavel
    Laznickova, Alice
    Laznicek, Milan
    Vera, Denis Rolando Beckford
    Beran, Milos
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2013, 56 (05): : 280 - 288
  • [38] Preclinical evaluation of a monoclonal antibody targeting the epidermal growth factor receptor as a radioimmunodiagnostic and radioimmunotherapeutic agent
    Ray, G. L.
    Baidoo, K. E.
    Wong, K. J.
    Williams, M.
    Garmestani, K.
    Brechbiel, M. W.
    Milenic, D. E.
    BRITISH JOURNAL OF PHARMACOLOGY, 2009, 157 (08) : 1541 - 1548
  • [39] Targeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies
    Erickson, Britt K.
    Zeybek, Burak
    Santin, Alessandro D.
    Fader, Amanda N.
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2020, 32 (01) : 57 - 64
  • [40] Targeting Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2) Expressing Bladder Cancer Using Combination Photoimmunotherapy (PIT)
    Siddiqui, Mohammad R.
    Railkar, Reema
    Sanford, Thomas
    Crooks, Daniel R.
    Eckhaus, Michael A.
    Haines, Diana
    Choyke, Peter L.
    Kobayashi, Hisataka
    Agarwal, Piyush K.
    SCIENTIFIC REPORTS, 2019, 9 (1)